Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial
- 1 September 2016
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 15 (10) , 1028-1034
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Thrombolysis in acute ischaemic stroke: time for a rethink?BMJ, 2015
- Effect of Alteplase Within 6 Hours of Acute Ischemic Stroke on All-Cause Mortality (Third International Stroke Trial)Stroke, 2014
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Questions about authorisation of alteplase for ischaemic strokeThe Lancet, 2014
- Do risks outweigh benefits in thrombolysis for stroke?BMJ, 2013
- Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trialThe Lancet Neurology, 2013
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One YearNew England Journal of Medicine, 1999
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995